CoronaVac

CGTN: China's COVID-19 vaccines proven safe, effective by trials and data

Retrieved on: 
Wednesday, January 18, 2023
Transport, Ageing, Foreign Affairs, Hospital, COVID-19 vaccine, World Health Organization, COVID-19, WHO, Government, Emergency Use Authorization, Safety, Ministry, CoronaVac, Nasal spray, Vaccine, Chinese Center for Disease Control and Prevention, Pfizer, Ministry of Foreign Affairs of the People's Republic of China, Tedros Adhanom, CDC, Pharmaceutical industry, Sinovac Biotech

BEIJING, Jan. 18, 2023 /PRNewswire/ -- COVID-19 vaccines produced in China have been proven to be safe and effective by clinical trials and real-world data.

Key Points: 
  • BEIJING, Jan. 18, 2023 /PRNewswire/ -- COVID-19 vaccines produced in China have been proven to be safe and effective by clinical trials and real-world data.
  • China is the only country with COVID-19 vaccines developed via multiple technical routes – they work in different ways.
  • Chinese companies also made viral vector vaccines and protein subunit vaccines to give people more options.
  • The Chinese vaccines are precious achievements of the country's fight against COVID-19, which also benefited people in many other countries.

CGTN: China's COVID-19 vaccines proven safe, effective by trials and data

Retrieved on: 
Tuesday, January 17, 2023
Transport, Ageing, Foreign Affairs, Hospital, COVID-19 vaccine, World Health Organization, COVID-19, WHO, Government, Emergency Use Authorization, Safety, Ministry, CoronaVac, Nasal spray, Vaccine, Chinese Center for Disease Control and Prevention, Pfizer, Ministry of Foreign Affairs of the People's Republic of China, Tedros Adhanom, CDC, Pharmaceutical industry, Sinovac Biotech

BEIJING, Jan. 17, 2023 /PRNewswire/ -- COVID-19 vaccines produced in China have been proven to be safe and effective by clinical trials and real-world data.

Key Points: 
  • BEIJING, Jan. 17, 2023 /PRNewswire/ -- COVID-19 vaccines produced in China have been proven to be safe and effective by clinical trials and real-world data.
  • China is the only country with COVID-19 vaccines developed via multiple technical routes – they work in different ways.
  • Chinese companies also made viral vector vaccines and protein subunit vaccines to give people more options.
  • The Chinese vaccines are precious achievements of the country's fight against COVID-19, which also benefited people in many other countries.

Pediatric Vaccines Global Markets Report 2022: Impacts of COVID-19, Market Revenue Data for 2020 and 2021, Estimates for 2022, and CAGR Projections through 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022
COVID-19, Consumer, Health, Pharmaceutical, Children, BCG, Investment, Incidence, Pfizer–BioNTech COVID-19 vaccine, CoronaVac, China National Pharmaceutical Group, Chickenpox, Pfizer, Vaccine, WHO, Dros, GlaxoSmithKline, Abbott Laboratories, Whooping cough, Mumps, Gavi, Merck & Co., Hepatitis, Measles, AstraZeneca, Global health, Child, Diphtheria, Mortality, Bharat Biotech, Vaccine-preventable diseases, Organization, COVID-19, Tetanus, UNICEF, Pharmaceutical industry

This report highlights the current and future market potential of pediatric vaccines and a detailed analysis of the market's drivers, challenges and opportunities.

Key Points: 
  • This report highlights the current and future market potential of pediatric vaccines and a detailed analysis of the market's drivers, challenges and opportunities.
  • The report also covers market projections through 2027 and estimates market shares for key players, as well as pediatric vaccines by type and by application.
  • The report also discusses the impact of the COVID-19 pandemic on this market.
  • Vaccines are one of the most significant advances in global health and are the most cost-effective strategy to reduce child mortality.

SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong

Retrieved on: 
Wednesday, August 3, 2022
Biotechnology, Pharmaceutical, General Health, Health, COVID-19, Children, Infectious Diseases, Consumer, NASDAQ, Vaccine, Safety, Foot-and-mouth disease virus, Minor, Department, R, Program, Center, Health Bureau, H5N1, WHO, Scientific Committee on Antarctic Research, Infection, HFMD, Sinovac Biotech, Mumps, III, Scientific Committee on Emerging and Newly Identified Health Risks, Polio, Chickenpox, Hepatitis A, COVID-19, CoronaVac, Company, EV71, Carrie Lam as Chief Executive of Hong Kong, Vaccination, Streptococcus, COVID-19 vaccine, Ageing, Zoonosis, Influenza A virus subtype H1N1, Government

The vaccination schedule for this age group follows the same vaccination schedule of older children.

Key Points: 
  • The vaccination schedule for this age group follows the same vaccination schedule of older children.
  • SINOVAC initiated its COVID-19 vaccine (CoronaVac) phase III clinical studies among children aged 6 months to 17 years since 2021.
  • Preliminary results show the vaccine has a good safety and immunogenicity profile, with no severe adverse reaction reported 6 months after two doses of vaccination among children aged 6 months to 35 months.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC COVID-19 Vaccine Is Authorized for Emergency Use in Kids Aged 3-5 In Brazil

Retrieved on: 
Thursday, July 14, 2022
COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, COVID-19, Influenza A virus subtype H1N1, Program, Pulmonology, Vaccine, H5N1, Infection, HFMD, SBP, WHO, Vaccination, Company, Hepatitis A, R, Mumps, Foot-and-mouth disease virus, Ageing, Brazilian Association of Investigative Journalism, Minor, SBI, Chickenpox, Instituto Butantan, Sinovac Biotech, Research, Association, CoronaVac, EV71, Streptococcus, To Brazil!, NASDAQ, Polio, Pharmaceutical industry, Brazilian Health Regulatory Agency, COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science

This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children.

Key Points: 
  • This authorization was given under comprehensive evaluations based on analysis results from all available data on the vaccine and its use in children.
  • To assist Anvisa in evaluating the vaccine, the experts from the above institutions had access to technical materials and research data on the vaccine.
  • CoronaVac has been authorized for emergency use for adults in Brazil since January 17, 2021.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

SINOVAC Polio Vaccine Prequalified by WHO

Retrieved on: 
Thursday, June 9, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, GPEI, World Health Organization, UN, Polio, OPV, Global Polio Eradication Initiative, Research, Food, Immunization, Infection, Influenza A virus subtype H1N1, United Nations, Poliovirus, VAPP, Polio eradication, Sinovac Biotech, Mouth, Environment, Hepatitis A, Pain, WHO, Fever, Chickenpox, Motor neuron, Vaccine, Feces, Campus Biotech, Saliva, COVID-19, NASDAQ, Prevalence, CoronaVac, Water, Public health, Mumps, Profile, EV71, World

The vaccine will be available for United Nations (UN) agencies to purchase to support the global polio endgame strategy.

Key Points: 
  • The vaccine will be available for United Nations (UN) agencies to purchase to support the global polio endgame strategy.
  • The vaccine can be used sequentially with oral polio attenuated live vaccine (OPV).
  • With the impact of the global COVID-19 pandemic, countries where wild polio strains still exist have experienced an increasing prevalence of polio cases.
  • SINOVAC has been continually dedicating itself to new vaccine research and development, with more combined and new technology vaccine products in the pipeline.

Clover’s COVID-19 Vaccine Candidate Demonstrates Durable High Protection and Immune Responses Against Omicron as a Booster

Retrieved on: 
Thursday, March 17, 2022
Omicron, CpG, Aluminium, Development, GLOBE, Immunization, Vaccine, WHO, SCB-2019, COVID-19, EMA, 1018, Forward-looking statement, Safety, Hospital, Severe acute respiratory syndrome coronavirus 2, Vaccine hesitancy, Paramount, Vaccination, LinkedIn, Pharmaceutical industry, Clover, Lancet, Trimer, CoronaVac

SHANGHAI, China, March 17, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 2197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced positive clinical results from several studies evaluating Clover’s COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), including follow-up efficacy at five months following primary vaccination and immune responses after a booster dose. Together, these results demonstrated durable, high efficacy after primary vaccination and robust immune response against Omicron as a booster and provide strong evidence for utilization of SCB-2019 (CpG 1018/Alum) for primary vaccination and as a universal COVID-19 booster candidate.

Key Points: 
  • Together, these results demonstrated durable, high efficacy after primary vaccination and robust immune response against Omicron as a booster and provide strong evidence for utilization of SCB-2019 (CpG 1018/Alum) for primary vaccination and as a universal COVID-19 booster candidate.
  • "SCB-2019 (CpG 1018/Alum) continues to demonstrate high and durable protection against COVID-19 as well as strong immune responses against Omicron when used as a booster," said Joshua Liang, Chief Executive Officer and Executive Director at Clover Biopharmaceuticals.
  • We look forward to continue working with global regulatory authorities to expedite the availability and equitable access of our COVID-19 vaccine candidate."
  • The growing body of clinical evidence demonstrate that SCB-2019 (CpG 1018/Alum) utilized as a universal booster can potentially induce significant and broadly-neutralizing immune responses against variants including Omicron.

Clover Provides Corporate Update and 2022 Priorities

Retrieved on: 
Monday, February 14, 2022
Temasek, Vaccine, Infection, NMPA, Adult, CoronaVac, LTA, UNICEF, EUL, TPO, WHO, Population, Person, Paramount, COVID-19, Variant, CpG, Hong Kong Stock Exchange, United Kingdom, APA, Purpura, Refrigeration, CIT, Quarantine, Licensure, Immunization, RNA transfection, PIP, GAVI, Bladder cancer, SCB-2019, COVAX, Aluminium, Eua Sunthornsanan, EMA, Profile, National Rural Development Partnership, 1018, Risk, International, IND, Safety, GMP, Commercial, Pediatrics, Severe acute respiratory syndrome coronavirus 2, Program, Vaccination, Public, GLOBE, Adolescence, IAP, Forward-looking statement, Transport, CDE, ITP, HKEX, Ascites, Omicron, AstraZeneca, CEPI, SMAC, CDMO, TRAIL, Pharmaceutical industry, Fine chemical, Clover, Lancet, Trimer

2021 was a transformative year for Clover and we are proud of the progress we have achieved.

Key Points: 
  • 2021 was a transformative year for Clover and we are proud of the progress we have achieved.
  • Clover received feedback from the WHO in December 2021 following their GMP inspection of the Clover Changxing manufacturing facility.
  • In early 2022, Clover decided to utilize an established CDMO site familiar to the EMA and WHO regulatory authorities to support and advance its EMA submission.
  • This plan provides Clover with a second pathway to potentially receive WHO EUL, a strategic approach to help ensure Clover can launch its COVID-19 vaccine globally as soon as possible.

Clover’s Final SPECTRA Phase 2/3 Clinical Trial Efficacy Data Is Published in The Lancet

Retrieved on: 
Friday, January 21, 2022
CoronaVac, Forward-looking statement, Vaccine, NMPA, Clinical trial, EMA, SCB-2019, COVID-19, Severe acute respiratory syndrome coronavirus 2, Safety, Adult, CpG, GLOBE, Aluminium, Vaccine hesitancy, WHO, Environment, Hospital, COVAX, 1018, Omicron, Pharmaceutical industry, Clover, Trimer, Lancet

(Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that final efficacy data from SPECTRA, a global Phase 2/3 clinical trial evaluating the efficacy, safety, and immunogenicity of its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), has been published in the peer-reviewed journal, The Lancet.

Key Points: 
  • (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that final efficacy data from SPECTRA, a global Phase 2/3 clinical trial evaluating the efficacy, safety, and immunogenicity of its COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), has been published in the peer-reviewed journal, The Lancet.
  • The paper, Efficacy of the adjuvanted subunit protein Covid-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial, may be accessed here .
  • The COVID-19 vaccine candidate also demonstrated 100% efficacy against severe COVID-19 and hospitalization caused by any strain of SARS-CoV-2 in SPECTRA.
  • We are pleased to have the SPECTRA pivotal Phase 2/3 trial results for Clovers COVID-19 vaccine candidate peer-reviewed and selected for publication in The Lancet, stated Dr. Ralf Clemens, Chairman of the Vaccine Scientific Advisory Board of Clover Biopharmaceuticals.

Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster

Retrieved on: 
Tuesday, January 11, 2022
Ageing, CoronaVac, Inhalation, Vaccination, Research, SSRN, Safety, Vaccine, RBD, CanSino Biologics, COVID-19, HKEX, Group, CRM197, Severe acute respiratory syndrome coronavirus 2, Public health, Recombinant, SSE, Immunity, Adenoviridae, Serum, RNA transfection, Trial of the century, Delta, Lancet

The results of the study indicated that a heterologous booster with one dose of the Inhalation Convideciafor adults aged 18 years and above, who have received two doses of inactivated COVID-19 vaccine, can induce a higher level of neutralizing antibodies than those with a homogeneous booster of inactivated vaccine.

Key Points: 
  • The results of the study indicated that a heterologous booster with one dose of the Inhalation Convideciafor adults aged 18 years and above, who have received two doses of inactivated COVID-19 vaccine, can induce a higher level of neutralizing antibodies than those with a homogeneous booster of inactivated vaccine.
  • CanSinoBIO's inhaled COVID-19 vaccine provides unique advantages and represents an innovative solution in response to the COVID-19 pandemic.
  • The data on safety results showed that there were fewer cases of adverse events after the heterologous booster of the Inhalation Convideciathan those administered with a homologous booster of inactivated vaccine.
  • The data on immunogenicity showed that the inhaled heterologous booster elicited a significantly higher level of neutralizing antibodies than those with a homogeneous booster of inactivated vaccine.